MaaT shoots for EU approval
But the timeline for a US green light is less clear, and the group has a cash crisis.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
Jemperli aims for ovarian white space
But, like Merck two weeks ago, GSK has failed to hit overall survival.
Affimed needs more time with AFM24
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
